Pfizer and Astellas’ Xtandi Shows Positive Results in Phase III EMBARK Study for Prostate Cancer
Partners Pfizer (NYSE: PFE) and Astellas Pharma Inc. (TYO: 4503) announced positive topline results from...
Pfizer
Pascal Qian Appointed General Manager of BMS China Unit
Pascal Qian this week officially assumed the role of General Manager of Bristol-Myers Squibb’s (BMS;...
QuantumPharm and Pfizer Expand Collaboration on Advanced Molecular Simulation Platform
Shenzhen-based QuantumPharm Inc., known as Xtalpi Inc. (HKG: 2228), has announced an expansion of its...
Pfizer’s Emblaveo Approved by China’s NMPA for Complex Infections
US giant Pfizer Inc., (NYSE: PFE) announced that it has received marketing approval from China’s...
Takeda’s Shan Guohong Departs to Join BeOne Medicines as Next Career Move
Shan Guohong, Global Senior Vice President of Takeda Pharmaceutical (TYO: 4502) and President of Takeda...
EU Approves Pfizer and Takeda’s Adcetris in Hodgkin Lymphoma Combination Regimen
Partners Pfizer (NYSE: PFE) and Takeda (TYO: 4502) announced that the European Commission (EC) has...
Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China
US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...
Pfizer Partners with HSITP to Boost Life Sciences Innovation in Greater Bay Area
US giant Pfizer Inc. (NYSE: PFE) has entered into a partnership with Hong Kong-Shenzhen Innovation...
Pfizer’s Q1 2025 Results: Revenues Down 6% YOY Amid Paxlovid, IRA Impact
US-based Pfizer Inc. (NYSE: PFE) released its Q1 2025 financial results, showing a -6% year-on-year...
Pfizer’s Inlyta Receives NMPA Approval for First-line Renal Cell Carcinoma Combination Therapy
US giant Pfizer Inc. (NYSE: PFE) announced last week that it has received marketing approval...
Pfizer Halts Development of Danuglipron Due to Drug-Induced Liver Injury Case
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has announced the termination of development for its...
Fujian Kerui’s Generic Sirolimus Gel Approved by China’s NMPA
China-based Fujian Kerui Pharmaceutical Co., Ltd. announced that its generic version of Pfizer’s (NYSE: PFE)...
Pfizer and Flagship Pioneering Collaborate on AI-Driven Drug Development
US pharmaceutical giant Pfizer Inc. (NYSE: PFE) has entered into a collaboration agreement with Flagship...
Pfizer Expands Abrysvo RSV Vaccine Indication to Include Ages 18-59 in EU
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has amended the marketing...
Genmab’s Tivdak Approved in Japan for Advanced Cervical Cancer Treatment
Denmark-based Genmab A/S (NASDAQ: GMAB) has secured approval from the Japan Ministry of Health, Labour...
Jiangsu Hengrui Pharmaceuticals Receives NMPA Approval for SHR-9803 and SHR-A2102 Clinical Trials
Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has announced receiving separate clinical trial approvals from...
Pfizer Restructures China Operations to Boost Growth and Innovation
US-based pharmaceutical giant Pfizer Inc. (NYSE: PFE) announced a significant leadership and organizational restructuring in...
Everest Medicines Initiates Jiashan Plant for Etrasimod Tablet Production
China-based Everest Medicines (HKG: 1952) announced the start of construction for a manufacturing plant in...
Basilea Pharmaceutica Marks Milestone as Cresemba Sales Soar in Asia Pacific
Switzerland-based Basilea Pharmaceutica Ltd (SWX: BSLN) announced that its antifungal Cresemba (isavuconazole), commercialized by Pfizer...
Arvinas and Pfizer Announce Positive Phase III Results for Vepdegestrant in ER+/HER2- Breast Cancer
Partners Arvinas, Inc. (NASDAQ: ARVN) and Pfizer Inc. (NYSE: PFE) announced positive topline results from...